KALV Benjamin L Palleiko sells $518K worth of shares
Jul 11, 2025, 4:35 AM
0.00%
What does KALV do
KalVista Pharmaceuticals, based in Cambridge, Massachusetts, specializes in small molecule protease inhibitors for unmet medical needs, focusing on hereditary angioedema treatments like sebetralstat and Factor XIIa inhibitors. The company went public in April 2015 and employs 150 staff.
Benjamin L Palleiko sold 32,979 shares of KALV on 9 July at $15.69 per share, worth a total of $518K. They now own 369,595 KALV shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
